Raze Therapeutics , a leading next generation cancer metabolism company, announced today the expansion of its Scientific Advisory Board with the addition of three leaders in oncology drug discovery and development. George Q. Daley, MD, PhD, the Samuel E. Lux IV Professor of Hematology/Oncology and Director of the Stem Cell Transplantation Program at Children's Hospital Boston; and Karen Vousden, PhD, Director of the Cancer Research UK Beatson Institute.
http://ift.tt/1xFV7Ov
http://ift.tt/1xFV7Ov
No comments:
Post a Comment